Day: September 25, 2025

DEME, through its Taiwanese joint venture CDWE, has secured a substantial contract for the Formosa 4 offshore wind farm in Taiwan, covering the transport and installation of 35 foundations and the offshore substation, as well as the scour protection works.AttachmentP2025 DEME Contract Formosa 4 20250925 ENG

(2025-09-25) Kitron announces that Chief Operating Officer Kristoffer Asklöv has tendered his resignation in order to assume the role of CEO at a Swedish manufacturing company outside Kitron’s competitive landscape. “Kristoffer has been a valued member of Kitron’s corporate management team since joining four years ago. His leadership and contributions have played a key role in our growth and operational development. We thank him for his dedication and wish him continued success in his new role,” says Peter Nilsson, CEO of Kitron. To ensure a smooth transition, Mr. Asklöv will remain with Kitron through the fourth quarter and leave the company at the end of the year. Mr. Asklöv’s responsibilities will be divided between Chief Technology Officer Stian Haugen and Hasse Faxe, who will join the corporate management team as Chief Commercial...

– Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services, has novated a contract from Venatorx Pharmaceuticals, Inc. (Venatorx) to Basilea to support the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase...

Press contact:Fahd PashaTel.: +1 647 860 3777E-mail: Fahd.Pasha@capgemini.com Banks face fallout as 40% of small and mid-sized merchant businesses eye shift to PayTechsMerchants face up to nine hours of downtime annually due to their current unreliable payment systems, increasing attractiveness of alternative PayTech1options PayTechs are winning the innovation race, with 60% adopting Gen AI across their operations, compared with 41% of banks Total worldwide non-cash transactions set to reach 3.5 trillion by 2029, led by rapid growth in Asia-Pacific regionParis, September 25, 2025 – The Capgemini Research Institute’s World Payments Report 2026, published today, highlights mounting pressure on banks to modernize their merchant services in the face of competition from more agile PayTechs, those firms that have been created specifically...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 2,843,987 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the public offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and offering expenses...

The prospectus supplement, the corresponding base shelf prospectus and any amendment to the documents are accessible through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) — Intermap Technologies Corporation (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company“), a global leader in 3D geospatial products and intelligence solutions, announced today that it has filed a prospectus supplement (the “Prospectus Supplement“) to its short form base shelf prospectus dated September 15, 2025 (the “Base Shelf Prospectus“) with respect to its previously announced bought deal public offering of 8,334,000 Class A common shares (the “Common Shares“) at a price of $3.00 per Common Share,...

VANCOUVER, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling organic certified, premium and super-premium cannabis products, is pleased to announce its participation in two upcoming investor-focused events: Small Cap Discoveries, taking place September 29–30 in Vancouver, and the Planet MicroCap Showcase: TORONTO, scheduled for October 21–23 in Toronto. Small Cap Discoveries – Vancouver Hosted at the Parq Hotel and Casino, Small Cap Discoveries is a curated event designed to connect engaged investors with high-potential Canadian growth companies. The conference features company presentations, keynote sessions, and one-on-one meetings, all aimed at fostering...

STEINHAUSEN, Switzerland, Sept. 24, 2025 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) (“Transocean”) announced today the pricing of an underwritten public offering of 125,000,000 Transocean shares, par value $0.10, at a public offering price of $3.05 per share. The offering reflects an increase from the 100,000,000 Transocean shares originally proposed to be sold. The gross proceeds to Transocean from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $381,250,000. All of the shares subject to the offering are being sold by Transocean. In addition, Transocean has granted the underwriters a 30-day option to purchase up to an additional 18,750,000 shares in the offering at the public offering price, less underwriting discounts and commissions. The offering...

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its upsized public offering of 11,108,055 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $199.9 million. All of the shares are being offered by MBX Biosciences. In addition, MBX Biosciences has granted the underwriters a 30-day option to purchase up to an additional 1,666,208 shares of common stock at the public offering price, less underwriting discounts and...